Advanced Solid Cancer Clinical Trial
Official title:
ORB-011 In Patients With Advanced Solid Tumors
The goal of this clinical research study is to determine if an investigational new drug, named ORB-011, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01416623 -
A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT03618043 -
Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Recruiting |
NCT03917043 -
APG-2449 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03884517 -
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
|
Phase 1 | |
| Recruiting |
NCT03791112 -
A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT04877717 -
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Recruiting |
NCT05770310 -
A Phase I Study Of JS015 in Patients With Advanced Solid Tumors
|
Phase 1 |